Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | GAA | P10253 | 5/20 | 0.52 |
| ▸ | GLA | P06280 | 4/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11369901 | 0.87 | CYP19A1 (0.51) | CYP11B1CYP19A1KDM4EGAAGLA | |
| SCHEMBL11368186 | 0.87 | CYP19A1 (0.51) | CYP19A1KDM4EGAAGLAPDPK1 | |
| SCHEMBL696285 | 0.83 | ACHE (0.56) | KDM4EPDPK1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL11377728 | 0.81 | SYK (0.60) | CYP19A1KDM4EGAAGLAPDPK1 | |
| SCHEMBL8219421 | 0.81 | KDM4E (0.47) | CYP19A1KDM4EGAAGLAPDPK1 | |
| SCHEMBL8218589 | 0.81 | KDM4E (0.49) | CYP19A1KDM4EGAAGLAPDPK1 | |
| SCHEMBL14727430 | 0.81 | CYP11B1 (0.57) | CYP11B1CYP19A1KDM4EALDH1A1CYP17A1 | |
| SCHEMBL14727429 | 0.81 | CYP11B1 (0.57) | CYP11B1CYP19A1KDM4EALDH1A1CYP17A1 | |
| SCHEMBL2155064 | 0.81 | CYP11B1 (0.61) | CYP11B1CYP19A1KDM4ECYP17A1CYP11B2 | |
| SCHEMBL11375277 | 0.79 | KDM4E (0.50) | CYP19A1KDM4EGAAGLAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104837832-B | GDF-8 inhibitors | 里格尔药品股份有限公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-106536507-A | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | 里格尔药品股份有限公司 | 2017-03-22 | — | — | CN | disclosed |
| US-8314123-B2 | 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2423196-A1 | 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof | Rexahn Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20120029012-A1 | 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF | REXAHN PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-8034829-B2 | e.g. 3-(3-methoxyphenyl)isoquinolin-1-amine; antiproliferative and antigrowth agent; breast tumors, prostate tumors, colon tumors, ovary tumors, kidney tumors, pancreas tumors, glioblastoma and melanoma. | REXAHN PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20080182871-A1 | 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182871-A1 | 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | FANCD2, NRAS, CCND2 | CYP11B1 155/4885CYP19A1 667/4885KDM4E 2109/4885 |
| US-20120029012-A1 | 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF | FANCD2, NRAS, CCND2 | CYP11B1 155/4885CYP19A1 667/4885KDM4E 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.